Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

Inclusion Criteria: * Subject must have histologically confirmed adenoid cystic carcinoma (ACC) of any primary site with distant metastases detected clinically or on imaging (biopsy of metastatic disease preferred, but not required) * Cohort 1 * One to five detectable sites of metastatic disease at any organ or site (including bone and CNS involvement) * Maximum size of 3 cm for brain lesions. * Note: Measurable disease is not required * Note: Patients with isolated intracranial disease for whom SRS would be the preferred standard of care are not eligible. * Note: Patients may have additional sites of disease for which radiation is not feasible or indicated provided this disease is: 1) Less than 1 cm in maximum diameter on most recent imaging; or 2) Stable over the last 3 months as determined by the investigator * Cohort 2 * At least 1 site of non-osseous disease * Cohort 1 * All (up to 5) metastatic foci should be amenable to SBRT as per review by a radiation oncologist based on protocol specified dose / dose constraints (there is no prespecified minimum or maximum size) * Cohort 2 * At least one metastatic focus amenable to local ablative treatment with any of the following: radiation therapy; radiofrequency, microwave, or cryoablation; bland or chemoembolization * Cohort 1 * Primary tumor either controlled, or amenable for local treatment with SBRT * Defined as no evidence of progression at primary or local site of disease (if known) with…